Filing Flows › Recursion Pharmaceuticals (RXRX) › Operating revenue revenue
Recursion Pharmaceuticals (RXRX) Operating revenue revenue by quarter
Recursion Pharmaceuticals' Operating revenue revenue was $18.1M in Q3 2026 (third quarter 2026), +147% from Q2 2026. Over the last 6 quarters it ranged from $5.0M (Q3 2025) to $35.4M (Q4 2025).
| Quarter | Operating revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $18.1M | +147% | +262% |
| Q2 2026 | $7.3M | +16% | -62% |
| Q1 2026 | $6.3M | -82% | — |
| Q4 2025 | $35.4M | +609% | — |
| Q3 2025 | $5.0M | -74% | — |
| Q2 2025 | $19.1M | — | — |
Q3 2026 at a glance
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Recursion Pharmaceuticals' Operating revenue revenue?
Recursion Pharmaceuticals' Operating revenue revenue was $18.1M in Q3 2026 (third quarter 2026), +147% from Q2 2026.
How has Recursion Pharmaceuticals' Operating revenue revenue changed?
Over the last 6 quarters it ranged from $5.0M (Q3 2025) to $35.4M (Q4 2025).
Q3 2026 results → · How Recursion Pharmaceuticals makes money →